Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

DNL747

Small molecule · developed by Denali Therapeutics

Phase 1 Most advanced trial (none active)
DNLI Developer
1 Registered trials

What is DNL747?

DNL747 is a drug studied in amyotrophic lateral sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Denali Therapeutics Inc. (DNLI)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03757351 Phase 1 Amyotrophic Lateral Sclerosis Terminated DNLI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyotrophic Lateral Sclerosis

More from Denali Therapeutics

Tividenofusp Alfa FDA approved DNL126 Phase 1/2 DNL201 Phase 1 DNL343 Phase 2/3 DNL593 Phase 1/2 DNL628 Phase 1 DNL919 Phase 1 DNL921 Phase 1 DNL952 Phase 1

Follow DNLI, the company behind DNL747

See DNLI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DNLI catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.